Location Directory

Clinical trials in Portland, Oregon

This page shows live ClinicalTrials.gov search results for Portland, Oregon, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

9377

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Painful Diabetic Neuropathy (PDN), Diabetic Nephropathies
Interventions: Cognitive Behavioral Therapy (CBT), Oral Medication, Topical Medication; Device · Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 23
States / cities: Stanford, California • Jacksonville, Florida • Chicago, Illinois + 17 more

Conditions: Aneurysm, Aneurysm, Intracranial
Interventions: Surpass Elite with Guardian Flow Diverter System; Device
Lead sponsor: Stryker Neurovascular; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 20
States / cities: Tucson, Arizona • Davis, California • Los Angeles, California + 17 more

Conditions: Breast Cancer
Interventions: Dato-DXd, Durvalumab, Pembrolizumab, Doxorubicin, Epirubicin, Cyclophosphamide, Paclitaxel, Carboplatin, Capecitabine, Olaparib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 58
States / cities: Daphne, Alabama • Prescott, Arizona • Jonesboro, Arkansas + 53 more

Conditions: Tobacco-Related Carcinoma, Smoking &Amp; Tobacco Cessation
Interventions: Enhanced Academic Detailing, Informational Intervention; Behavioral · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 9,133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Head and Neck Cancer
Interventions: cisplatin, 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy; Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2031
U.S. locations: 259
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 196 more

Conditions: Gout, Gouty Arthritis
Interventions: Pharmacist-Led; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 5
States / cities: Omaha, Nebraska • Portland, Oregon • Philadelphia, Pennsylvania + 2 more

Conditions: Newly Diagnosed Multiple Myeloma (NDMM)
Interventions: AZD0120, Cyclophosphamide, Fludarabine, Melphalan (part of ASCT), Lenalidomide; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2039
U.S. locations: 46
States / cities: Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 37 more

Conditions: Opioid Dependence, Substance Abuse Disorders, Complex Medical Patients, Primary Care Patients With Chronic Conditions
Interventions: MOUD "Plus" Intervention (treatment as usual + coordinated counseling and referral to community based peer), Treatment As Usual (primary care with low threshold MOUD prescribing); Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Untreated Follicular Lymphoma
Interventions: Surovatamig, R-CHOP, R-CVP, BR; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 62
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 56 more

Conditions: Dementia Moderate, Dementia, Mild, Alzheimer Disease
Interventions: Xanamem, Placebo; Drug
Lead sponsor: Actinogen Medical; Industry
Eligibility: 50 Years and older
Enrollment: 247 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 19
States / cities: Carlsbad, California • Sherman Oaks, California • Denver, Colorado + 16 more

Conditions: Androgenetic Alopecia
Interventions: Topical SM04554 solution, Topical vehicle solution; Drug
Lead sponsor: Biosplice Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 24
States / cities: Encinitas, California • San Diego, California • New Haven, Connecticut + 20 more

Conditions: Crohn's Disease
Interventions: Duvakitug, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 16 Years to 80 Years
Enrollment: 980 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 127
States / cities: Peoria, Arizona • Scottsdale, Arizona • Tucson, Arizona + 107 more

Clinical trials in Portland, Oregon

Filter and sort this location

Live official records

Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Electronic Quitline Referral With Enhanced Academic Detailing for the Promotion of Smoking Cessation

Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery

Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Disorder Seen In Primary Care

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease

A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease